Questions

1. Clinical Diagnosis:
   • Acute urticaria (seafood/crustacean-induced).
2. Three Cardinal Morphological Features:
   • Sharply circumscribed, raised, superficial wheals/edema with central swelling surrounded by reflex erythema.
   • Intense pruritus (occasionally associated with a burning sensation).
   • Transient, evanescent nature (individual lesions characteristically resolve within 30 minutes to 24 hours without leaving post-inflammatory hyperpigmentation or cutaneous scarring).
3. Immunopathology and Primary Mediator:
   • Mechanism: Type I (immediate-type) Gell-Coombs hypersensitivity reaction mediated by allergen-specific IgE antibodies bound to high-affinity receptors ($Fc\varepsilon RI$) on dermal mast cells and circulating basophils, leading to antigen cross-linking and explosive degranulation.
   • Primary Mediator: Preformed histamine (acting primarily via endothelial and nerve ending $H_1$ receptors), accompanied by synthesized leukotrienes ($LTC_4, LTD_4$) and platelet-activating factor (PAF), causing arteriolar vasodilation, increased capillary postcapillary venular permeability, and stimulation of unmyelinated C-nerve fibers.
4. First-Line Pharmacotherapy:
   • Second-generation (non-sedating) $H_1$ antihistamine:
     • Cetirizine: $5\text{ mg}$ (or $0.25\text{ mg/kg/dose}$) orally once daily; OR
     • Levocetirizine: $2.5\text{ mg}$ orally once daily; OR
     • Fexofenadine: $30\text{ mg}$ orally twice daily.
5. Red-Flag Signs Mandating Intramuscular Epinephrine:
   • Upper airway compromise: Stridor, hoarseness of voice, difficulty swallowing, or acute tongue/uvular angioedema.
   • Lower airway involvement: Tachypnea, wheezing, cough, retractions, or acute bronchospasm.
   • Hemodynamic instability: Hypotension, prolonged capillary refill time ($>3\text{ seconds}$), syncope, or diaphoresis.
   • Persistent gastrointestinal distress: Cramping abdominal pain or recurrent vomiting.

1. Specific Clinical Diagnosis:
   • Allergic rhinitis.
2. ARIA Consensus Classification:
   • Classification Schema:
     • Frequency: Intermittent ($<4\text{ days/week}$ or $<4\text{ consecutive weeks}$) vs. Persistent ($\ge 4\text{ days/week}$ and $\ge 4\text{ consecutive weeks}$).
     • Severity: Mild (no sleep disturbance, no impairment of daily activities/school, normal speech) vs. Moderate-Severe (presence of one or more items: sleep disturbance, impairment of daily activities/leisure/sports, impairment of school/work, troublesome symptoms).
   • Patient's Stratification: Moderate-to-severe persistent allergic rhinitis.
3. Characteristic Physical Signs (Allergic Stigmata):
   • Allergic shiners: Symmetrical infraorbital dark circles secondary to chronic venous congestion in the retro-orbital and nasal submucosal plexuses.
   • Allergic salute / Transverse nasal crease: Habitual upward rubbing of the nasal tip leading to a permanent horizontal hypopigmented or hyperpigmented cutaneous groove across the lower third of the nose.
   • Dennie-Morgan folds: Accentuated infraorbital skin creases radiating beneath the lower eyelids caused by recurrent local edema.
   • Allergic gape: Chronic mouth-breathing facies due to severe bilateral nasal airway obstruction and turbinate hypertrophy.
4. First-Line Maintenance Pharmacotherapy:
   • Drug Class: Intranasal Corticosteroids (INCS).
   • Preferred Agents and Dosing:
     • Mometasone furoate: $50\text{ mcg/spray}$, 1 spray in each nostril once daily (total daily dose $100\text{ mcg}$); OR
     • Fluticasone furoate: $27.5\text{ mcg/spray}$, 1 spray in each nostril once daily (total daily dose $55\text{ mcg}$).
5. Second-Line / Add-on Options:
   • Oral non-sedating second-generation $H_1$ antihistamines (e.g., Cetirizine $2.5-5\text{ mg}$ once daily, or Levocetirizine $2.5\text{ mg}$ once daily).
   • Leukotriene receptor antagonists (e.g., Montelukast $4\text{ mg}$ orally once daily at bedtime for a 4-year-old).
   • Intranasal antihistamines (e.g., Azelastine nasal spray, 1 spray per nostril twice daily).

1. Targeted Agent Mechanism of Action:
   • Dupilumab: Fully human monoclonal antibody directed against the shared Interleukin-4 receptor alpha subunit ($IL\text{-}4R\alpha$), concurrently inhibiting both $IL\text{-}4$ and $IL\text{-}13$ signal transduction cascades via the Type I and Type II receptor complexes.
   • Omalizumab: Recombinant DNA-derived humanized IgG1k monoclonal antibody that selectively binds to the constant ($C\varepsilon 3$) domain of free circulating Immunoglobulin E (IgE), preventing its interaction with high-affinity ($Fc\varepsilon RI$) and low-affinity ($Fc\varepsilon RII / CD23$) receptors on mast cells and basophils.
   • Mepolizumab: Humanized IgG1k monoclonal antibody that selectively targets and neutralizes circulating Interleukin-5 (IL-5) cytokine, preventing its binding to the alpha subunit of the IL-5 receptor complex.
   • Crisaborole: Topical small-molecule Phosphodiesterase-4 (PDE4) inhibitor, which increases intracellular cyclic adenosine monophosphate (cAMP) levels, thereby downregulating inflammatory cytokine production.
   • Abrocitinib: Oral selective Janus kinase-1 (JAK1) inhibitor, which downregulates intracellular cytokine signaling downstream of the $IL\text{-}4, IL\text{-}13, IL\text{-}22, IL\text{-}31$, and thymic stromal lymphopoietin (TSLP) pathways.
2. Mepolizumab vs. Benralizumab:
   • Mepolizumab binds directly to the circulating soluble IL-5 cytokine ligand, neutralizing its ability to stimulate eosinophil production, differentiation, and survival.
   • Benralizumab binds directly to the alpha subunit of the IL-5 receptor ($IL\text{-}5R\alpha$) on human eosinophils and basophils and induces direct, rapid antibody-dependent cell-mediated cytotoxicity (ADCC) via natural killer (NK) cells, causing targeted depletion of target cells.
3. Approved Indications and Age Thresholds:
   • Dupilumab: Approved for moderate-to-severe atopic dermatitis (children $\ge 6\text{ months}$ of age); add-on maintenance for moderate-to-severe eosinophilic/Type 2 asthma (children $\ge 6\text{ years}$ of age).
   • Omalizumab: Approved for moderate-to-severe persistent allergic asthma with positive skin test or in vitro reactivity to a perennial aeroallergen and elevated baseline IgE (children $\ge 6\text{ years}$ of age); chronic spontaneous urticaria refractory to $H_1$ antihistamines (children $\ge 12\text{ years}$ of age).
4. Pre-treatment Screening for Systemic JAK Inhibitors:
   • Latent tuberculosis screening (Tuberculin Skin Test / QuantiFERON-TB Gold assay and chest radiography).
   • Viral hepatitis serologies (HBsAg, anti-HBc, anti-HCV) and baseline complete blood count (absolute lymphocyte count, absolute neutrophil count, and hemoglobin), renal function, liver enzymes, and lipid profile.

1. Diagnosis and Hypersensitivity Type:
   • Diagnosis: Vaccine-triggered Anaphylaxis (severe multi-organ, life-threatening allergic reaction).
   • Classification: Type I Gell-Coombs immediate hypersensitivity reaction.
2. First-Line Medication Order & Calculation:
   • Drug: Epinephrine (Adrenaline).
   • Concentration: $1:1,000\text{ dilution}$ ($1\text{ mg/mL}$).
   • Route: Intramuscular (IM) injection.
   • Anatomic Site: Anterolateral aspect of the mid-thigh (vastus lateralis muscle).
   • Calculation:
     $$ > \begin{aligned} > \text{Recommended dose} &= 0.01\text{ mg/kg} \\ > \text{Patient weight} &= 9\text{ kg} \\ > \text{Calculated absolute dose} &= 9\text{ kg} \times 0.01\text{ mg/kg} = \mathbf{0.09\text{ mg}} \\ > \text{Volume of } 1:1,000 \ (1\text{ mg/mL}) &= \frac{0.09\text{ mg}}{1\text{ mg/mL}} = \mathbf{0.09\text{ mL}} > \end{aligned} > $$
     (Administer immediately using a $1\text{ mL}$ tuberculin/insulin-type syringe. Dose may be repeated every $5\text{ to }15\text{ minutes}$ as clinically indicated).
3. Fluid Resuscitation Calculation:
   $$ > \begin{aligned} > \text{Fluid of Choice} &= \text{Isotonic crystalloid (Balanced Salt Solution / 0.9\% Normal Saline)} \\ > \text{Bolus Volume} &= 10\text{ to }20\text{ mL/kg over } 5\text{--}10\text{ minutes} \\ > \text{Calculation for } 9\text{ kg} &= 9\text{ kg} \times 20\text{ mL/kg} = \mathbf{180\text{ mL}} \quad (\text{Range: } 90\text{--}180\text{ mL}) > \end{aligned} > $$
4. Refractory Anaphylaxis & Next Step:
   • Definition: Anaphylaxis that persists despite two or more appropriately dosed, timely intramuscular epinephrine injections along with adequate fluid resuscitation.
   • Next Step: Continuous intravenous (IV) epinephrine infusion initiated at $0.05\text{ to }0.1\text{ mcg/kg/min}$, titrated every $2\text{ to }5\text{ minutes}$ against arterial blood pressure, airway patency, and tissue perfusion markers.
5. Observation Duration and Rationale:
   • Minimum Duration: Minimum of 6 to 12 hours of continuous in-hospital monitoring (extended to 24 hours for severe or refractory episodes).
   • Clinical Phenomenon: Biphasic anaphylactic reaction (recurrence of life-threatening allergic symptoms within $1\text{ to }72\text{ hours}$ without re-exposure to the offending allergen, occurring in up to $5\text{--}20\%$ of all anaphylaxis presentations).

1. Diagnosis and Diaper Area Sparing:
   • Diagnosis: Atopic dermatitis (infantile phase).
   • Diaper Area Sparing: The diaper microenvironment provides occlusion and high ambient humidity that prevents stratum corneum dehydration, water evaporation, and transepidermal water loss (TEWL). Additionally, it shields the covered skin from direct mechanical scratching and excoriation.
2. Hanifin and Rajka Major Criteria (must fulfill at least 3 of 4):
   • Pruritus.
   • Typical morphology and age-specific distribution (facial and extensor involvement in infants; flexural lichenification in older children).
   • Chronic or chronically relapsing dermatitis.
   • Personal or family history of atopic diseases (asthma, allergic rhinitis, atopic dermatitis).
3. SCORAD Index Formula & Domains:
   $$ > \begin{aligned} > \mathbf{\text{SCORAD}} &= \frac{A}{5} + \frac{7B}{2} + C \\ > \text{Where:} & \\ > A &= \text{Extent: Percentage of body surface area involved (0--100 using Rule of Nines)} \\ > B &= \text{Intensity: Sum of 6 individual clinical morphological signs (0--18)} \\ > &\quad (\text{Erythema, Edema/Papulation, Oozing/Crusting, Excoriation, Lichenification, Dryness;} \\ > &\quad \text{each graded } 0 = \text{absent}, 1 = \text{mild}, 2 = \text{moderate}, 3 = \text{severe}) \\ > C &= \text{Subjective symptoms: Combined Visual Analog Scale (0--20)} \\ > &\quad (\text{Pruritus score } [0\text{--}10] + \text{Sleep loss score } [0\text{--}10]) > \end{aligned} > $$
4. Stepped Acute Flare Management:
   • Skin Barrier Restoration (Basic Therapy):
     • Daily bathing in lukewarm water for $5\text{ to }10\text{ minutes}$ with fragrance-free, soap-free syndet cleansers.
     • "Soak and Seal" technique: Generous application of ceramide-dominant, lipid-replenishing bland ointment/emollient within 3 minutes of patting dry, applied 3–4 times daily.
   • Topical Anti-Inflammatory Therapy:
     • Class: Low-potency topical corticosteroid (Class VII).
     • Agent: Hydrocortisone 1% ointment, applied in a thin layer to active erythematous lesions twice daily for 5 to 7 days until acute erythema subsides, followed by tapering or transition to proactive intermittent therapy (twice weekly).
5. Topical Calcineurin Inhibitors (Steroid-Sparing Alternatives):
   • Tacrolimus ointment (0.03%): Approved for moderate-to-severe atopic dermatitis in children $\ge 2\text{ years}$ of age (the $0.1\%$ concentration is approved for adolescents $\ge 16\text{ years}$).
   • Pimecrolimus cream (1%): Approved for mild-to-moderate atopic dermatitis in children $\ge 2\text{ years}$ of age.

1. Very High Potency (Class I): Clobetasol propionate 0.05% (contraindicated in infants and on facial/intertriginous sites).
2. High Potency (Class II/III): Betamethasone dipropionate 0.05%, Mometasone furoate 0.1% ointment.
3. Medium Potency (Class IV/V): Fluticasone propionate 0.05% cream, Hydrocortisone butyrate 0.1%.
4. Low Potency (Class VI/VII): Desonide 0.05%, Hydrocortisone acetate 1% (safest for infant facial, neck, and diaper-adjacent application).

Finger Tip Unit (FTU) Concept:
One FTU is the amount of ointment expressed from a tube with a 5 mm diameter nozzle applied from the distal interphalangeal crease to the fingertip of an adult index finger ($\approx 0.5\text{ g}$).

• $1\text{ FTU}$ covers an area equivalent to two adult palms.
• An infant's face and neck require approximately $1.5\text

1. Diagnosis: Chédiak–Higashi syndrome (CHS).
2. Genetics and Cellular Pathophysiology:
   • Gene & Locus: Autosomal recessive mutation in the LYST (CHS1) gene located on chromosome 1q42.1–q42.2, encoding the lysosomal trafficking regulator protein.
   • Mechanism of Hypopigmentation: Defective vesicular sorting and lysosomal trafficking lead to aberrant fusion and formation of giant, clumped melanosomes within melanocytes, impeding normal dendritic transfer of melanin to adjacent keratinocytes and hair shafts.
3. Neurological Manifestations:
   • Progressive peripheral sensorimotor neuropathy (areflexia, foot drop).
   • Cerebellar ataxia and dysmetria.
   • Cranial nerve palsies, intellectual decline, Parkinsonian-like tremors, and refractory seizures.
4. Complication & Definitive Management:
   • Complication: "Accelerated phase" (Hemophagocytic Lymphohistiocytosis / HLH) characterized by non-malignant lymphohistiocytic proliferation, hemophagocytosis, pancytopenia, coagulopathy, and multiorgan dysfunction (frequently triggered by Epstein-Barr virus infection).
   • Definitive Cure: Allogeneic Hematopoietic Stem Cell Transplantation (HSCT), ideally performed prior to the onset of the accelerated phase.

graph TD
    A[Mutation in LYST / CHS1 Gene] --> B[Abnormal Organelle Fusion & Vesicular Trafficking]
    B --> C[Giant Azurophilic Granules in Leukocytes]
    B --> D[Giant Melanosomes in Melanocytes]
    B --> E[Platelet Dense Granule Defects]
    C --> F[Defective Phagosome-Lysosome Fusion & Impaired Cytotoxicity]
    D --> G[Oculocutaneous Albinism & Silvery Hair]
    E --> H[Mild Bleeding Diathesis]
    F --> I[Recurrent Pyogenic Infections]
    F --> J[Accelerated Phase / Secondary HLH]

While HSCT successfully corrects the immunological and hematological defects (including prevention of the accelerated phase), it does not halt or reverse progressive neurodegenerative decline, which is increasingly recognized as patients survive into late childhood and adulthood.

1. Diagnosis: Common Variable Immunodeficiency (CVID).
2. Diagnostic Criteria (ESID / PAGID Criteria):
   • Significant decrease in serum IgG (at least 2 standard deviations below age-adjusted mean) along with a marked reduction in at least one other immunoglobulin isotype (IgA or IgM).
   • Failure of specific antibody response to protein (e.g., tetanus toxoid) or polysaccharide (e.g., unconjugated pneumococcal) vaccines.
   • Onset of immunodeficiency at age > 2 years (usually diagnosed in older children or adults).
   • Exclusion of secondary causes of hypogammaglobulinemia (protein-losing enteropathy, nephrotic syndrome, medications) and other defined genetic primary immunodeficiencies (e.g., X-linked agammaglobulinemia, hyper-IgM syndrome).
3. Cellular Defect:
   • Defective terminal differentiation of phenotypically normal mature B cells into functional plasma cells and memory B cells (CD27+), leading to impaired immunoglobulin class-switching and defective somatic hypermutation despite normal or near-normal circulating CD19+ B-cell numbers.
4. Long-Term Management:
   • Immunoglobulin Replacement: Intravenous Immunoglobulin (IVIG) at a replacement dose of 400–600 mg/kg every 3 to 4 weeks (or Subcutaneous Immunoglobulin [SCIG] 100–150 mg/kg weekly) targeting trough IgG levels > 700–800 mg/dL.
   • Infection Prophylaxis: Long-term prophylactic Co-trimoxazole (trimethoprim 5 mg/kg/day once daily) or Azithromycin (10 mg/kg thrice weekly) for recurrent sinopulmonary infections, along with aggressive screening and antimicrobial eradication of Giardia lamblia or Campylobacter enteritis.

1. Diagnosis & Subtype:
   • Ehlers-Danlos Syndrome (EDS).
   • Classical EDS (cEDS) (Type I/II).
2. Valvular Pathology & Surveillance:
   • Valvular Lesion: Mitral Valve Prolapse (MVP) with or without mitral regurgitation.
   • Surveillance Modality: Transthoracic Echocardiography (TTE) with color Doppler (to evaluate for MVP, tricuspid valve prolapse, and aortic root dilation).
3. Cutaneous Scarring & Diagnostic Testing:
   • Scar Type: "Cigarette paper" scars (atrophic, widened, papyraceous parchment-like scars).
   • Diagnostic Tests:
     • Molecular genetic testing: Next-Generation Sequencing (NGS) gene panel identifying heterozygous pathogenic variants in COL5A1, COL5A2, or rarely COL1A1.
     • Skin biopsy with dermal fibroblast culture: Assessment of type V collagen synthesis or ultrastructural transmission electron microscopy demonstrating disorganized collagen fibrils ("collagen flowers").
4. Complications of Vascular EDS (vEDS / Type IV):
   • Spontaneous arterial aneurysm, dissection, or fatal rupture (most commonly thoracic/abdominal aorta, mesenteric, or renal arteries).
   • Spontaneous bowel perforation (predominantly sigmoid colon).
   • Spontaneous rupture of the gravid uterus during the third trimester of pregnancy or peripartum.

1. Classification of Adverse Food Reactions:
   • Immune-mediated (Food Allergy): IgE-mediated, Non-IgE-mediated, and Mixed (IgE and cell-mediated).
   • Non-immune-mediated (Food Intolerance): Metabolic/enzymatic (e.g., lactase deficiency), toxic/pharmacological (e.g., scombroid poisoning, caffeine), and idiosyncratic.
2. Definitions:
   • FPIES: Food Protein-Induced Enterocolitis Syndrome.
   • FDEIA: Food-Dependent Exercise-Induced Anaphylaxis.
3. Comparison of FPIES vs. FDEIA:
   • Immunological Mechanism: FPIES is non-IgE, T-cell/cell-mediated gastrointestinal mucosal inflammation with systemic cytokine release; FDEIA is IgE-mediated hypersensitivity with exercise acting as an essential cofactor lowering mast-cell degranulation thresholds.
   • Onset Latency: FPIES symptoms develop 1 to 4 hours (typically 2 hours) post-ingestion; FDEIA requires ingestion followed within 2 to 4 hours by vigorous physical exercise.
   • Organ System Involvement: FPIES manifests exclusively with profound gastrointestinal signs (repetitive emesis, delayed diarrhea) and systemic hypovolemia/shock without cutaneous or respiratory signs; FDEIA exhibits classical multisystem anaphylaxis (urticaria, angioedema, bronchospasm, cardiovascular collapse).
4. Immediate Emergency Management of Severe FPIES:
   • Fluid Resuscitation: Immediate intravenous access and bolus infusion of isotonic crystalloid (Normal Saline 0.9% or Ringer's Lactate) at 20 mL/kg over 15 to 30 minutes, repeated as necessary to restore perfusion and blood pressure.
   • Antiemetic / Anti-inflammatory Therapy: Intravenous Ondansetron (0.15 mg/kg, max 4 mg) to arrest protracted emesis; Intravenous Methylprednisolone (1 mg/kg) in severe protracted episodes to suppress cytokine-driven gut inflammation. Note: Epinephrine is not routinely indicated unless fluid-refractory hemodynamic collapse occurs.

1. Diagnosis: Granulomatosis with Polyangiitis (GPA) (formerly Wegener's granulomatosis).
2. Serological Biomarker:
   • Cytoplasmic antineutrophil cytoplasmic antibodies (c-ANCA) detected by indirect immunofluorescence.
   • Anti-Proteinase 3 antibodies (Anti-PR3) quantified by enzyme-linked immunosorbent assay (ELISA).
3. Gold Standard Diagnostic Test & Histological Triad:
   • Gold Standard: Tissue biopsy (nasal mucosa, lung parenchyma, or renal biopsy showing pauci-immune crescentic necrotizing glomerulonephritis).
   • Histological Triad:
     • Systemic necrotizing vasculitis of small-to-medium vessels (arteries, arterioles, capillaries, venules).
     • Granulomatous inflammation with multinucleated giant cells.
     • Extensive geographic parenchymal tissue necrosis.
4. Induction Remission Protocol:
   • Corticosteroids: Intravenous Methylprednisolone pulse therapy at 30 mg/kg/day (maximum 1 g/day) for 3 consecutive days, followed by oral Prednisolone at 1–2 mg/kg/day (maximum 60 mg/day), tapered gradually over 6 months.
   • Immunosuppression:
     • Option A: Intravenous Rituximab (anti-CD20 monoclonal antibody) at 375 mg/m²/dose once weekly for 4 consecutive weeks.
     • Option B: Intravenous Cyclophosphamide at 500–750 mg/m²/dose every 3 to 4 weeks for 3 to 6 pulses (along with Mesna for uroprotection).
   • Infection Prophylaxis: Co-trimoxazole (trimethoprim 5 mg/kg/day) three times weekly for Pneumocystis jirovecii pneumonia prophylaxis during induction.

1. Histopathology showing granulomatous inflammation
2. Upper airway involvement (chronic purulent/bloody nasal discharge, saddle nose deformity, septal perforation)
3. Laryngo-tracheo-bronchial involvement (subglottic stenosis)
4. Pulmonary involvement (chest radiograph/CT with fixed infiltrates, nodules, or cavitation)
5. ANCA positivity (PR3-ANCA or c-ANCA)
6. Renal involvement (proteinuria, hematuria, or pauci-immune necrotizing crescentic glomerulonephritis)

GPA has high sensitivity for PR3-ANCA (> 80–90%), unlike Microscopic Polyangiitis (MPA) which is typically MPO-ANCA (p-ANCA) positive and lacks granulomas and cavitary lesions.

1. Diagnosis & EULAR/PRINTO/PRES Consensus Criteria:
   • Diagnosis: Henoch-Schönlein Purpura (IgA Vasculitis).
   • Mandatory Criterion: Palpable purpura (commonly in crops) or petechiae with lower extremity predominance, without thrombocytopenia or coagulopathy.
   • Plus at least ONE of the following four criteria:
     • Diffuse abdominal pain: Acute, colicky pain (may include gastrointestinal bleeding, intussusception).
     • Histopathology: Leukocytoclastic vasculitis with predominant IgA deposition or IgA-dominant proliferative glomerulonephritis.
     • Arthritis or Arthralgia: Acute joint swelling or joint pain with limitation of movement.
     • Renal involvement: Proteinuria (>0.3 g/24 h or urine protein-to-creatinine ratio >0.5 mg/mg) or hematuria (>5 RBCs/HPF or red blood cell casts).
2. Gastrointestinal Complications:
   • Intussusception, extensive bowel ischemia, intestinal necrosis, intestinal perforation, and massive gastrointestinal hemorrhage.
   • Anatomical distinction: HSP-associated intussusception is typically ileo-ileal (60–70% of cases) due to focal intramural submucosal hematoma acting as a pathological lead point, whereas idiopathic infantile intussusception is predominantly ileo-colic.
3. Mathematical Derivation & Corticosteroid Regimen:
   $$ > \begin{aligned} > \text{uPCR} &= \frac{\text{Urinary Protein } (\text{mg/dL})}{\text{Urinary Creatinine } (\text{mg/dL})} \\ > \text{Significant Proteinuria Cutoff} &= \mathbf{>0.5\text{ mg/mg}} \quad (\text{Normal in } >2\text{ yr: } <0.2\text{ mg/mg}) \\ > \text{Nephrotic-range Cutoff} &= \mathbf{>2.0\text{ mg/mg}} > \end{aligned} > $$
   • Indications for Corticosteroids: Severe refractory abdominal pain, massive GI hemorrhage, symptomatic scrotal orchitis, severe disabling arthritis, or crescentic IgA nephritis.
   • Dosing: Oral Prednisolone:
     • Dose: $1\text{ to }2\text{ mg/kg/day}$ (maximum $60\text{ mg/day}$) orally for $1\text{ to }2\text{ weeks}$, followed by a gradual taper over the subsequent $2\text{ to }3\text{ weeks}$.
     • For a 16 kg child: $16\text{ to }32\text{ mg/day}$ in divided doses.
4. Steroid-Sparing Agent & Pre-Treatment Testing:
   • Drug: Dapsone at a dose of $1\text{ to }2\text{ mg/kg/day}$ orally (maximum $100\text{ mg/day}$).
   • Mandatory Pre-treatment Screen: Quantitative Glucose-6-Phosphate Dehydrogenase (G6PD) assay (to prevent drug-induced severe hemolytic anemia) and baseline Complete Blood Count with reticulocyte count and liver function tests.

1. Diagnosis & Inheritance:
   • Diagnosis: Hereditary Angioedema (HAE).
   • Inheritance: Autosomal dominant with variable penetrance (due to heterozygous mutations in the SERPING1 gene on chromosome 11q12.1; ~20–25% arise from de novo mutations).
2. Molecular Pathophysiology & Key Mediator:
   • Deficiency or functional defect of plasma C1-esterase inhibitor (C1-INH) leads to failure of intrinsic inhibition of the contact/kallikrein-kinin and fibrinolytic pathways.
   • Unregulated activation of factor XII and plasma prekallikrein generates excessive plasma kallikrein, which cleaves high-molecular-weight kininogen (HMWK).
   • Primary Mediator: Bradykinin. Binding of excessive bradykinin to constitutive vascular Bradykinin $\text{B}_2$ receptors causes widespread endothelial cell contraction, vasodilation, and extravasation of intravascular fluid into subcutaneous and submucosal tissues.
3. Diagnostic Screening Cascade:
   • Serum C4 level: Initial screening test; persistently decreased ($<50\%$ of normal) in $>95\%$ of patients even during asymptomatic periods.
   • C1-INH Antigenic Protein Level:
     • Type 1 HAE (85% of cases): Markedly low ($<50\%$ normal).
     • Type 2 HAE (15% of cases): Normal or elevated (dysfunctional protein produced).
   • C1-INH Functional Activity Assay: Markedly decreased ($<50\%$ of normal) in both Type 1 and Type 2 HAE.
   • C1q Level: Normal in HAE (used to exclude Acquired Angioedema, where C1q is low).
4. Acute Emergency Management:
   • Airway: Immediate endotracheal intubation or surgical airway (cricothyroidotomy) if laryngeal compromise/stridor develops; unresponsive to antihistamines, steroids, or epinephrine.
   • First-line Targeted Therapies:
     • Plasma-derived human C1-INH concentrate (pdC1-INH; Berinert): $\mathbf{20\text{ IU/kg}}$ IV push over 5–10 minutes.
     • Selective Bradykinin $\text{B}_2$ Receptor Antagonist (Icatibant): Subcutaneous injection in the abdominal area. Dosing by body weight:
       • $12\text{ to }25\text{ kg}$: $10\text{ mg}$ SC
       • $26\text{ to }65\text{ kg}$: $15\text{ mg}$ SC
       • $>65\text{ kg}$: $30\text{ mg}$ SC
     • Recombinant human C1-INH (Ruconest): $\mathbf{50\text{ IU/kg}}$ IV (maximum 4200 IU) for adolescents $\ge13$ years.
   • Second-line Option (when specific agents are unavailable):
     • Solvent-detergent treated Fresh Frozen Plasma (FFP): $\mathbf{10\text{ to }15\text{ mL/kg}}$ IV (caution: contains kallikrein substrates that can theoretically transiently worsen edema before providing inhibitor).

1. Pathogen & Underlying Diagnosis:
   • Pathogen: Pneumocystis jirovecii (demonstrated by Gomori methenamine silver positive cyst walls).
   • Primary Immunodeficiency: Hyper-IgM Syndrome (HIGM type 1 / X-linked Hyper-IgM).
2. Molecular Defect & Cellular Interaction:
   • Gene & Locus: Mutation in the CD40LG (CD154) gene located on chromosome Xq26.3.
   • Cellular Defect: Loss of functional CD40 Ligand expression on activated CD4+ T helper cells.
   • Disrupted Interaction: Impaired binding of CD40L (on T cells) to the CD40 receptor (on B cells, monocytes, and dendritic cells). This abolishes B-cell immunoglobulin class-switch recombination (isotype switching from IgM to IgG, IgA, and IgE), impairs somatic hypermutation, and paralyzes T-cell-mediated CD40 signaling required for macrophage activation against opportunistic pathogens.
3. Autosomal Recessive Molecular Etiologies:
   • AICDA gene mutation (Activation-Induced Cytidine Deaminase deficiency, HIGM2).
   • CD40 gene mutation (CD40 receptor deficiency, HIGM3).
   • UNG gene mutation (Uracil-DNA Glycosylase deficiency, HIGM5).
4. Curative & Weight-Based Acute Antimicrobial Therapy:
   • Curative Therapy: Allogeneic Hematopoietic Stem Cell Transplantation (HSCT).
   • Acute Pneumocystis Antimicrobial Dosing (for 8 kg child):
     $$ > \begin{aligned} > \text{TMP Component Dose} &= 15\text{ to }20\text{ mg/kg/day IV divided q6h} \\ > &= 15 \times 8 \text{ to } 20 \times 8 = \mathbf{120\text{ to }160\text{ mg/day of TMP}} \\ > \text{SMX Component Dose} &= 75\text{ to }100\text{ mg/kg/day IV divided q6h} \\ > &= 75 \times 8 \text{ to } 100 \times 8 = \mathbf{600\text{ to }800\text{ mg/day of SMX}} \\ > \text{Individual Dose} &= \mathbf{30\text{ to }40\text{ mg TMP / } 150\text{ to }200\text{ mg SMX IV every 6 hours}} \\ > \text{Duration} &= \mathbf{21\text{ days}} > \end{aligned} > $$
   • Adjunctive Therapy: Intravenous methylprednisolone ($1\text{ mg/kg}$ IV every 6 to 12 hours) tapered over 21 days for moderate-to-severe hypoxemia ($\text{PaO}_2 <70\text{ mm Hg}$ or $\text{SaO}_2 <92\%$), alongside regular Intravenous Immunoglobulin (IVIG) substitution at $400\text{ to }600\text{ mg/kg}$ every 3 to 4 weeks.

1. Definitive Diagnosis & Essential Baseline Investigations:

   • Diagnosis: Polyarticular Juvenile Idiopathic Arthritis (polyJIA) — specifically rheumatoid factor (RF)-negative or RF-positive pending serology (involvement of $\ge 5$ joints during the first 6 months of disease in a child $< 16$ years, persisting $> 6$ weeks, with other etiologies excluded).
   • Four Essential Baseline Investigations:
     • Erythrocyte Sedimentation Rate (ESR) and C-reactive Protein (CRP) (systemic inflammation markers)
     • Rheumatoid Factor (RF) (tested twice, 3 months apart, to classify subtype)
     • Antinuclear Antibodies (ANA) by indirect immunofluorescence (identifies risk for asymptomatic uveitis)
     • Baseline Complete Blood Count (CBC) with differential and platelet count (evaluates anemia of chronic disease and thrombocytosis)

2. Ophthalmological Complication and Surveillance:

   • Complication: Chronic anterior uveitis (iridocyclitis) — typically asymptomatic, non-granulomatous, and insidiously progressive.
   • Screening Modality: Slit-lamp biomicroscopy (to detect anterior chamber cells and flare).
   • Key Risk Factors:
     • Positive Antinuclear Antibody (ANA) serology
     • Young age at onset ($< 6$ years)
     • Female sex / Oligoarticular or RF-negative polyarticular subtype

3. Mechanism of Action Matching:

   • Methotrexate: Dihydrofolate reductase inhibitor / antimetabolite (csDMARD; inhibits purine synthesis and elevates anti-inflammatory extracellular adenosine).
   • Adalimumab: Recombinant fully human monoclonal antibody against Tumor Necrosis Factor-alpha (anti-TNF-$\alpha$).
   • Abatacept: Soluble cytotoxic T-lymphocyte-associated antigen 4 immunoglobulin (CTLA-4-Ig) fusion protein; selective T-cell co-stimulation modulator (blocks CD80/CD86 binding to CD28).
   • Tocilizumab: Humanized monoclonal antibody directed against the Interleukin-6 (IL-6) receptor.
   • Rituximab: Chimeric monoclonal antibody targeting the CD20 antigen on B lymphocytes (causes selective B-cell depletion).

4. Treatment Protocol and Corticosteroid Indications:

   • First-line csDMARD Regimen:
     $$ > \begin{aligned} > \text{Methotrexate Dose} &= 10\text{ to }15\text{ mg/m}^2/\text{week} \quad (\text{or } 0.5\text{ to }1.0\text{ mg/kg/week; max } 25\text{ mg/week}) \\ > &= 10\text{ mg orally or subcutaneously once weekly} \\ > \text{Adjuvant Folate} &= \text{Folic acid } 1\text{ mg orally daily (or } 5\text{ mg once weekly, } 24\text{ h post-methotrexate)} > \end{aligned} > $$
   • Indications for Systemic Corticosteroids in PolyJIA:
     • Temporary "bridging" therapy to achieve rapid symptomatic relief while awaiting the onset of action of csDMARDs or biologics (which take 6–12 weeks).
     • Severe, incapacitating disease flares causing profound functional disability.
     • Systemic crisis or failure to tolerate intra-articular corticosteroid joint injections across multiple affected joints.

• RF-Negative Polyarticular JIA: Accounts for 20–30% of JIA; bimodal age peak (early childhood 2–4 years and late childhood 6–12 years); intermediate uveitis risk if ANA positive.
• RF-Positive Polyarticular JIA: Accounts for 5–10% of JIA; resembles adult rheumatoid arthritis; typically adolescent onset, positive for anti-CCP antibodies, higher propensity for erosive articular destruction, and carries a low uveitis risk.

Screening Frequency for Chronic Anterior Uveitis (American College of Rheumatology Guidelines):

• High Risk (Oligoarticular / RF-negative Polyarticular + ANA positive + age $< 7$ years + disease duration $< 4$ years): Slit-lamp examination every 3 months.
• Moderate Risk (ANA negative + age $< 7$ years, or ANA positive with disease duration $> 4$ years): Slit-lamp examination every 6 months.
• Low Risk (RF-positive Polyarticular): Slit-lamp examination every 12 months.

1. Primary Clinical Diagnosis:
   • Complete (Classic) Kawasaki Disease (fever ≥ 5 days accompanied by ≥ 4 of the 5 principal clinical features: bilateral non-purulent conjunctivitis, oral mucosal changes, peripheral extremity changes, polymorphous exanthem, and unilateral cervical lymphadenopathy ≥ 1.5 cm).
2. Characteristic Laboratory Abnormalities:
   • Markedly elevated acute-phase reactants: Erythrocyte sedimentation rate (ESR > 40 mm/hr) and C-reactive protein (CRP ≥ 3 mg/dL).
   • Reactive thrombocytosis (platelet count > 450,000/μL, typically peaking in the 2nd to 3rd week).
   • Normocytic, normochromic anemia and leukocytosis with neutrophilic predominance (left shift).
   • Hypoalbuminemia (serum albumin ≤ 3.0 g/dL) and elevated serum transaminases (ALT/AST).
   • Sterile pyuria (≥ 10 WBCs/HPF on clean-catch urine showing mononuclear leukocytes).
3. Cardiovascular Complication and Timeline:
   • Coronary artery aneurysms (CAA), thrombosis, and myocardial infarction.
   • Peak incidence: Subacute phase, typically between 2 to 4 weeks (14–28 days) from fever onset.
4. First-Line Pharmacological Regimen:
   • Intravenous Immunoglobulin (IVIG):
     • Dose: $2\text{ g/kg}$ single infusion ($24\text{ g}$ total for a 12 kg child).
     • Route and Rate: Intravenous over 10 to 12 hours.
   • Aspirin (Acetylsalicylic Acid):
     • Acute anti-inflammatory phase: $30\text{ to }50\text{ mg/kg/day}$ (or $80\text{ to }100\text{ mg/kg/day}$ per AHA guidelines) divided into 4 doses orally every 6 hours ($360\text{ to }600\text{ mg/day}$ in 4 divided doses of $90\text{ to }150\text{ mg}$) until afebrile for 48–72 hours.
     • Convalescent antiplatelet phase: Reduce to $3\text{ to }5\text{ mg/kg/day}$ orally as a single daily dose ($36\text{ to }60\text{ mg/day}$) continued for 6 to 8 weeks, provided follow-up echocardiography shows normal coronary arteries.

1. Dose, Route, Frequency, and Calculation:
   $$ > \begin{aligned} > \text{Weekly Dose} &= 10\text{ to }15\text{ mg/m}^2/\text{week} \\ > &= 0.8\text{ m}^2 \times 15\text{ mg/m}^2/\text{week} \\ > &= \mathbf{12\text{ mg/week}} \quad (\text{Subcutaneous or Oral, ONCE weekly}) > \end{aligned} > $$
   • Administered strictly once weekly (oral bioavailability is enhanced when administered fasting; subcutaneous route is preferred for doses $\ge 15\text{ mg/m}^2$ or when gastrointestinal intolerance occurs).
2. Mechanism of Action in Rheumatic Disease:
   • Low-dose weekly methotrexate competitively inhibits 5-aminoimidazole-4-carboxamide ribonucleotide (AICAR) transformylase and thymidylate synthase.
   • This leads to intracellular accumulation of AICAR, which inhibits AMP deaminase and adenosine deaminase, causing extracellular release and accumulation of adenosine.
   • Extracellular adenosine binds to $A_{2A}$ purinergic receptors on immune cells, suppressing neutrophil chemotaxis, suppressing pro-inflammatory cytokine secretion (TNF-$\alpha$, IL-1, IL-6), and promoting anti-inflammatory cytokine release (IL-10).
3. Critical Adverse Effects & Laboratory Surveillance:
   • Hepatotoxicity (transaminitis, steatosis, hepatic fibrosis; monitored via AST, ALT, albumin).
   • Bone marrow suppression (leukopenia, neutropenia, thrombocytopenia, megaloblastic anemia; monitored via complete blood count with differential).
   • Gastrointestinal toxicity and stomatitis (nausea, vomiting, oral aphthous ulcerations).
   • Pulmonary toxicity (hypersensitivity pneumonitis / interstitial lung disease).
4. Micronutrient Co-prescription:
   • Folic Acid: $1\text{ mg/day}$ orally daily (or $5\text{ mg}$ orally once weekly).
   • Timetable: Must be omitted on the day of Methotrexate administration (or taken 24–48 hours after the weekly Methotrexate dose) to prevent competitive reduction of Methotrexate anti-inflammatory efficacy while effectively mitigating mucosal, hematological, and hepatic toxicity.

1. Probable Clinical Diagnosis:
   • Post-infectious Reactive Arthritis (Reiter syndrome / Post-dysenteric reactive arthritis).
2. HLA Association:
   • HLA-B27.
   • Prevalence: Positive in approximately $65\%\text{ to }80\%$ of pediatric cases (significantly higher than the general population frequency of $6\text{ to }8\%$).
3. Triggering Bacterial Pathogens:
   • Enteric pathogens: Campylobacter jejuni, Salmonella enterica (serovars Typhimurium/Enteritidis), Shigella flexneri, Yersinia enterocolitica.
   • Genitourinary pathogens: Chlamydia trachomatis, Mycoplasma genitalium.
4. Stepwise Pharmacological Management:
   • First-line systemic therapy: Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) at anti-inflammatory doses:
     • Naproxen: $15\text{ to }20\text{ mg/kg/day}$ orally divided every 12 hours ($150\text{ to }200\text{ mg}$ twice daily for a 20 kg child) for 4 to 8 weeks.
     • Alternative: Ibuprofen $30\text{ to }40\text{ mg/kg/day}$ orally divided every 8 hours.
   • Intra-articular Corticosteroid Therapy:
     • Triamcinolone hexacetonide ($1\text{ mg/kg}$ for large joints like the knee) if severe single-joint effusion persists despite 2–4 weeks of NSAIDs.
   • Disease-Modifying Anti-Rheumatic Drugs (DMARDs):
     • Sulfasalazine ($30\text{ to }50\text{ mg/kg/day}$ divided every 12 hours) reserved for chronic arthritis persisting $> 3\text{ months}$ or failure of local therapy.
   • Note: Antimicrobial eradication is indicated only if active enteric or chlamydial infection is microbiologically confirmed at presentation; routine post-infectious reactive arthritis does not benefit from empiric antibiotics once the inciting gut mucosal infection has cleared.

1. Humoral (B-Cell) Screening Investigations:
   • Quantitative:
     • Serum quantitative immunoglobulin levels (IgG, IgA, IgM, and IgE) measured by nephelometry and interpreted against age-adjusted reference ranges.
     • Flow cytometric enumeration of circulating peripheral blood B-lymphocytes (CD19+ and CD20+ surface marker percentage and absolute count).
   • Functional (Qualitative):
     • Isohemagglutinin titers (naturally occurring IgM antibodies against ABO blood group antigens anti-A and anti-B).
     • Specific post-vaccination antibody titers to protein antigens (tetanus toxoid, diphtheria toxoid) and T-cell independent polysaccharide antigens (pneumococcal capsular polysaccharide).
2. Complement Pathway Screening Assays:
   • Classical Pathway: Total Hemolytic Complement assay ($\text{CH}_{50}$).
   • Alternative Pathway: Alternative Pathway Hemolytic assay ($\text{AH}_{50}$ or $\text{AP}_{50}$).
3. Indications for Hematopoietic Stem Cell Transplantation (HSCT):
   • Severe Combined Immunodeficiency (SCID, any genetic variant).
   • Wiskott-Aldrich Syndrome (WAS).
   • Severe Congenital Neutropenia (Kostmann disease) refractory to recombinant G-CSF.
   • Chronic Granulomatous Disease (CGD) with intractable or recurrent life-threatening infections.
   • Familial Hemophagocytic Lymphohistiocytosis (HLH).
   • Leukocyte Adhesion Deficiency Type 1 (LAD-1, severe phenotype with $< 1\%$ CD18 expression).
4. Contraindicated Live-Attenuated Vaccines:
   • Bacille Calmette-Guérin (BCG) vaccine.
   • Oral Poliovirus Vaccine (OPV).
   • Live-attenuated Rotavirus vaccine.
   • Measles, Mumps, and Rubella (MMR) or Varicella vaccine.

1. Diagnostic Classification:
   • Stevens-Johnson Syndrome / Toxic Epidermal Necrolysis (SJS/TEN) Overlap:
     • SJS: $< 10\%$ total body surface area (TBSA) epidermal detachment.
     • SJS/TEN Overlap: $10\%\text{ to }30\%$ TBSA epidermal detachment (patient has 18%).
     • TEN: $> 30\%$ TBSA epidermal detachment.
2. Prognostic Scoring System & Parameters:
   • SCORTEN (Score of Toxic Epidermal Necrolysis) (calculated within first 24 hours):
     • Age $\ge 40\text{ years}$ (0 points if pediatric).
     • Heart rate $\ge 120\text{ beats/min}$ (present in this patient).
     • Underlying malignancy / hematologic neoplasia.
     • Body surface area detachment $> 10\%$ on Day 1 (present in this patient).
     • Serum Urea $> 10\text{ mmol/L}$ ($> 28\text{ mg/dL}$).
     • Serum Glucose $> 14\text{ mmol/L}$ ($> 252\text{ mg/dL}$).
     • Serum Bicarbonate $< 20\text{ mEq/L}$.
3. Emergency Resuscitation & Pharmacotherapy:
   • Immediate Cessation: Immediately stop carbamazepine and all non-essential medications; identify cross-reactive aromatic anticonvulsants (phenytoin, phenobarbital) as strictly contraindicated.
   • Critical Care & Fluids: Admit to Pediatric Intensive Care Unit (PICU) or Burn Center in an ambient thermoneutral room ($30\text{ to }32^\circ\text{C}$).
     • Fluid replacement: Balanced crystalloid (Ringer's lactate) calculated at $2\text{ to }3\text{ mL/kg/}\% \text{TBSA detachment}$ over the first 24 hours:
       $$ > \begin{aligned} > \text{24-hr Fluid} &= 2\text{ mL} \times 25\text{ kg} \times 18 \\ > &= \mathbf{900\text{ mL Ringer's Lactate}} \quad (\text{plus maintenance fluids}) > \end{aligned} > $$
     • Titrate to maintain urine output at $1.0\text{ to }1.5\text{ mL/kg/hour}$.
   • Specific Immunomodulatory Regimen:
     • Intravenous Immunoglobulin (IVIG): $1\text{ to }2\text{ g/kg}$ total dose infused over 2 to 4 days (blocks Fas-FasL-mediated keratinocyte apoptosis); OR
     • Cyclosporine: $3\text{ to }5\text{ mg/kg/day}$ divided every 12 hours enterally or intravenously for 10–14 days, then tapered.
4. Organ-Specific Supportive Interventions:
   • Ophthalmologic Care:
     • Urgent ophthalmology consult within 24 hours.
     • Instillation of preservative-free artificial tears every 1 to 2 hours and prophylactic topical antibiotic drops (e.g., moxifloxacin).
     • Daily sweeps of superior and inferior fornices with a moistened, sterile glass rod to disrupt fibrous bands and prevent symblepharon formation, ankyloblepharon, and cicatricial entropion.
     • Application of amniotic membrane grafting if extensive epithelial loss or limbal stem cell deficiency develops.
   • Enteral Nutritional & Mucosal Care:

1. Clinical Diagnosis & Image Finding:
   • Diagnosis: Systemic Lupus Erythematosus (SLE) presenting with lupus nephritis and neuropsychiatric SLE (NPSLE).
   • Exhibit finding: Classical malar (butterfly) rash—erythematous, fixed maculopapular rash over the malar eminences with prominent sparing of the nasolabial folds.
2. Confirmatory Autoantibodies & Clinical Significance:
   • Anti-double-stranded DNA (anti-dsDNA): Highly specific for SLE (>95%); titers correlate directly with disease activity, active lupus nephritis flares, and complement consumption (low C3/C4).
   • Anti-Smith (anti-Sm): Most specific antibody for SLE (>99%), remains stable over time (does not fluctuate with disease activity), serving as a definitive diagnostic marker.
3. 2019 EULAR/ACR Classification Criteria:
   • Mandatory Entry Criterion: Antinuclear antibody (ANA) titer $\ge 1:80$ on HEp-2 cells or an equivalent positive test at least once.
   • Threshold: A cumulative weighted score of $\ge 10$ points across clinical (constitutional, hematologic, neuropsychiatric, mucocutaneous, serosal, musculoskeletal, renal) and immunologic domains (antiphospholipid antibodies, complement proteins, SLE-specific antibodies).
4. Induction Immunosuppressive Protocol:
   • Intravenous Methylprednisolone pulse therapy: $30\text{ mg/kg/day}$ (maximum $1000\text{ mg/day}$) IV infused over 60 minutes once daily for 3 consecutive days.
   • Followed by Oral Prednisolone: $1.5\text{ to }2\text{ mg/kg/day}$ (maximum $60\text{ mg/day}$) in divided doses.
   • Cyclophosphamide (NIH/Euro-Lupus regimen): Intravenous pulse cyclophosphamide $500\text{ to }750\text{ mg/m}^2$ monthly for 6 months (or oral Mycophenolate Mofetil $1200\text{ to }1800\text{ mg/m}^2/\text{day}$ in 2 divided doses), combined with Mesna for uroprotection during cyclophosphamide infusions.
   • Adjuvant Therapy: Hydroxychloroquine $5\text{ mg/kg/day}$ orally (maximum $400\text{ mg/day}$) for background disease control and thromboprophylaxis.

1. Diagnosis:
   • Takayasu Arteritis (also historically designated as "Pulseless Disease" or "Non-specific Aortoarteritis").
2. Vessels Involved:
   • Primary vessel: Aorta (aortic arch, descending thoracic aorta, abdominal aorta).
   • Major branches: Subclavian arteries (left > right), carotid arteries, renal arteries, and mesenteric vessels.
3. EULAR/PRINTO/PReS Classification Criteria:
   • Mandatory Criterion: Angiographic abnormalities (conventional DSA, CT angiography, or MR angiography) of the aorta or its main branches and pulmonary arteries demonstrating aneurysm, dilatation, stenosis, occlusion, or thickened arterial wall.
   • Plus at least ONE of the following four criteria:
     • Pulse deficit or claudication: Decreased, absent, or unequal peripheral artery pulses or claudication of extremities.
     • Blood pressure discrepancy: Systolic blood pressure difference $>10\text{ mm Hg}$ between any two limbs.
     • Bruits: Audible bruits over large arteries (carotid, subclavian, abdominal aorta).
     • Hypertension: Blood pressure $>95\text{th}$ percentile for age, sex, and height.
4. Medical Induction Therapy:
   • High-dose Systemic Corticosteroids:
     • Intravenous Methylprednisolone pulse: $30\text{ mg/kg/day}$ (maximum $1000\text{ mg/day}$) IV for 3 consecutive days for acute limb-threatening ischemia or accelerated renovascular hypertension.
     • Followed by Oral Prednisolone: $1\text{ to }2\text{ mg/kg/day}$ (maximum $60\text{ mg/day}$) tapered slowly over several months based on ESR/CRP and clinical response.
   • Disease-Modifying Antirheumatic Drug (Steroid-sparing agent):
     • Methotrexate: $15\text{ mg/m}^2/\text{week}$ (or $0.3\text{ to }0.5\text{ mg/kg/week}$, maximum $25\text{ mg/week}$) orally or subcutaneously, administered with folic acid supplementation ($1\text{ mg/day}$ except on the day of methotrexate); OR Tocilizumab (anti-IL-6 receptor antagonist) $8\text{ to }12\text{ mg/kg}$ IV every 2–4 weeks in refractory cases.

1. Lesion Description & Diagnosis:
   • Lesion: Giant cobblestone papillae (hypertrophied, flattened polygonal papillae $>1\text{ mm}$ in diameter) on the superior palpebral/tarsal conjunctiva.
   • Diagnosis: Vernal Keratoconjunctivitis (VKC)—palpebral/tarsal form.
2. Pathophysiologic Vulnerability:
   • Direct Aeroallergen Exposure: The conjunctival mucosa has direct contact with the external environment, facilitating allergen deposition and cross-linking of surface IgE.
   • Mast Cell & Eosinophil Hyperdensity: The ocular substantia propria possesses one of the highest densities of resident mast cells ($\sim 5,000/\text{mm}^3$) along with an amplified Th2-skewed cytokine milieu (IL-4, IL-5, IL-13) that promotes persistent eosinophil chemotaxis.
3. Pathognomonic Limbus Signs:
   • Horner-Trantas dots (gelatinous white-yellow clumps composed of degenerated eosinophils and epithelial debris situated at the superior corneal limbus).
4. Stepwise Pharmacological Management:
   • Mild-to-Moderate Maintenance:
     • Dual-action mast cell stabilizer/H1-antihistamine: Olopatadine hydrochloride ophthalmic solution $0.1\%$ (1 drop in each eye twice daily) or $0.2\%$ (1 drop once daily), or Ketotifen $0.025\%$ twice daily.
     • Preservative-free lubricating artificial tears: 4–6 times daily to flush allergens.
   • Severe Disease / Refractory Flares:
     • Short-course "soft" topical corticosteroids: Fluorometholone $0.1\%$ or Loteprednol etabonate $0.2\%$, 1 drop 3–4 times daily tapered rapidly over 7–14 days (strict monitoring of intraocular pressure to prevent steroid-induced glaucoma/cataracts).
     • Topical Calcineurin Inhibitors (steroid-sparing): Cyclosporine A $0.05\%\text{ to }0.1\%$ eye drops twice daily OR Tacrolimus $0.03\%\text{ to }0.1\%$ eye ointment applied once or twice daily into the lower conjunctival fornix.

1. Diagnosis, Gene & Locus:
   • Diagnosis: Wiskott-Aldrich Syndrome (WAS).
   • Defective Gene: WAS gene encoding Wiskott-Aldrich Syndrome protein (WASP).
   • Chromosomal Locus: X-chromosome, short arm: Xp11.22–p11.23 (X-linked recessive inheritance).
2. Distinguishing Platelet Feature:
   • Microthrombocytopenia (thrombocytopenia with abnormally small platelets, characterized by a markedly reduced Mean Platelet Volume, $\text{MPV} < 5\text{ to }6\text{ fL}$).
   • Contrast with ITP: ITP exhibits normal or increased MPV with large/giant mega-thrombocytes.
3. Serum Immunoglobulin Profile:
   • Serum IgM: Decreased (low).
   • Serum IgA: Elevated (high).
   • Serum IgE: Elevated (high).
   • Serum IgG: Normal to slightly decreased (with severe deficiency in specific IgG2 subclass response to polysaccharide antigens).
4. Curative Treatment:
   • Allogeneic Hematopoietic Stem Cell Transplantation (HSCT): Curative therapy of choice using an HLA-matched sibling or matched unrelated donor, performed as early as possible.
   • Alternative/Novel Curative: Autologous hematopoietic stem cell gene therapy (using lentiviral vectors expressing WASP) for patients lacking a suitable donor.

1. Underlying Disorder & Gene:
   • Diagnosis: X-Linked Agammaglobulinemia (XLA) / Bruton Agammaglobulinemia.
   • Mutated Gene: BTK gene (encoding Bruton Tyrosine Kinase) located on chromosome Xq22.1–q22.2.
2. Flow Cytometry Findings:
   • CD19+ / CD20+ B lymphocytes: Severely reduced to virtually absent ($< 1\%$ to $2\%$ of total circulating lymphocytes).
   • CD3+ T lymphocytes: Normal or elevated in relative percentage ($> 90\%$) with preserved total absolute CD3+ counts and normal in vitro mitogen proliferation.
3. Serum Immunoglobulin Profile:
   • Total Serum IgG: Markedly reduced, typically $< 100\text{ to }200\text{ mg/dL}$ (often $< 100\text{ mg/dL}$).
   • Serum IgM: Markedly reduced to undetectable ($< 10\text{ to }20\text{ mg/dL}$).
   • Serum IgA: Markedly reduced to undetectable ($< 10\text{ mg/dL}$).
4. Lifetime Maintenance Therapy:
   • Intravenous Immunoglobulin (IVIG):
     • Dose: $400\text{ to }600\text{ mg/kg}$ IV administered every 3 to 4 weeks.
     • OR Subcutaneous Immunoglobulin (SCIG): $100\text{ to }150\text{ mg/kg}$ administered once weekly.
     • Therapeutic Goal: Maintain steady-state serum IgG trough levels $\ge 700\text{ to }800\text{ mg/dL}$ (or $> 1000\text{ mg/dL}$ in patients with structural airway disease such as bronchiectasis).
   • Absolute Contraindication: Live viral vaccines (e.g., OPV, MMR, Varicella, Rotavirus) are strictly contraindicated for the patient and household contacts.